Activity of Tigecycline Tested against a Worldwide Collection of Vancomycin-Resistant Enterococci
Activity of Tigecycline Tested against a Worldwide Collection of Vancomycin-Resistant Enterococci, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Antimicrobial Susceptibility of Gram-positive Organisms Isolated in Latin American Hospitals: Evaluation of the Emergence and Dissemination of Vancomycin-Resistant Enterococci
Antimicrobial Susceptibility of Gram-positive Organisms Isolated in Latin American Hospitals: Evaluation of the Emergence and Dissemination of Vancomycin-Resistant Enterococci, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Susceptibility Pattern of Gram-positive Organisms Isolated in Australian Medical Centers (2004, 2006-2007): Results from a Multi-Center Prospective Surveillance Program
Susceptibility Pattern of Gram-positive Organisms Isolated in Australian Medical Centers (2004, 2006-2007): Results from a Multi-Center Prospective Surveillance Program, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Decreasing Susceptibility Rates Among Acinetobacter spp. Clinical Isolates Collected Worldwide (2005-2008)
Decreasing Susceptibility Rates Among Acinetobacter spp. Clinical Isolates Collected Worldwide (2005-2008), Lead author: Mendes RE, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Emergence of blaOXA-48 among Enterobacter cloacae in Argentina and its Prevalence among Carbapenem Non-Susceptible Enterobacteriaceae
Emergence of blaOXA-48 among Enterobacter cloacae in Argentina and its Prevalence among Carbapenem Non-Susceptible Enterobacteriaceae, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Emergence of OXA-48 Carbapenemases among Klebsiella spp. from India
Emergence of OXA-48 Carbapenemases among Klebsiella spp. from India, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
High Prevalence of CTX-M-Producing Isolates and Emergence of KPC-Encoding Genes in the Western United States
High Prevalence of CTX-M-Producing Isolates and Emergence of KPC-Encoding Genes in the Western United States, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Diversity of Acquired Ribosomal RNA Methylase Genes Encoding Aminoglycoside Resistance in the Asia-Pacific Region
Diversity of Acquired Ribosomal RNA Methylase Genes Encoding Aminoglycoside Resistance in the Asia-Pacific Region, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Recommended Ulifloxacin MIC Quality Control Ranges for Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study Design
Recommended Ulifloxacin MIC Quality Control Ranges for Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Streit J, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Initial Quality Control Ranges for CEM-102 (Fusidic Acid) Using the CLSI Multi-Laboratory M23-A3 Study Design
Initial Quality Control Ranges for CEM-102 (Fusidic Acid) Using the CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Recently Approved Tigecycline Susceptibility Breakpoints for S. pneumoniae and H. influenzae: Do Broth Microdilution and Disk Diffusion Results Agree?
Recently Approved Tigecycline Susceptibility Breakpoints for S. pneumoniae and H. influenzae: Do Broth Microdilution and Disk Diffusion Results Agree?, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Minocycline Using Gram-Positive and Gram-Negative Organisms
A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Minocycline Using Gram-Positive and Gram-Negative Organisms, Lead author: Knapp C, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Epidemiologic Detection Of Carbapenemase-producing Klebsiella spp. By EUCAST or CLSI Clinical Breakpoints
Epidemiologic Detection Of Carbapenemase-producing Klebsiella spp. By EUCAST or CLSI Clinical Breakpoints, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Iclaprim Using Fastidious and Non-Fastidious Gram-Positive Organisms
A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Iclaprim Using Fastidious and Non-Fastidious Gram-Positive Organisms, Lead author: Bastulli, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
A Multi-Site Study Comparing an 18-24h Susceptibility System to the CLSI Broth Microdilution Method for Telavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms
A Multi-Site Study Comparing an 18-24h Susceptibility System to the CLSI Broth Microdilution Method for Telavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms, Lead author: Holliday, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Activity of Ceftaroline against Emerging Serotypes of Streptococcus pneumoniae
Activity of Ceftaroline against Emerging Serotypes of Streptococcus pneumoniae, Lead author: Jacobs, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Antimicrobial Activity of Ceftaroline Tested against Streptococci from United States and European Medical Centers: Results from the Ceftaroline Longitudinal Assessment of Spectrum and Susceptibility (CLASS) Program
Antimicrobial Activity of Ceftaroline Tested against Streptococci from United States and European Medical Centers: Results from the Ceftaroline Longitudinal Assessment of Spectrum and Susceptibility (CLASS) Program, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
In Vitro Activity and In Vivo Efficacy of (S)-3(aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride Compound : A Gram-negative Antimicrobial
In Vitro Activity and In Vivo Efficacy of (S)-3(aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride Compound : A Gram-negative Antimicrobial, Lead author: Alley, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Spectrum and Activity of Ceftaroline Combined with NXL-104 Tested against a Challenge Collection of Pathogens with Well Characterized Resistances
Spectrum and Activity of Ceftaroline Combined with NXL-104 Tested against a Challenge Collection of Pathogens with Well Characterized Resistances, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Bactericidal Activity of Ceftaroline Combined with NXL-104 against Critical Targeted Organisms Possessing Various Resistance Mechanisms
Bactericidal Activity of Ceftaroline Combined with NXL-104 against Critical Targeted Organisms Possessing Various Resistance Mechanisms, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin Derivative for Oral Use in Humans
In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin Derivative for Oral Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
In Vitro Antibacterial Spectrum of BC-7013, a Novel Pleuromutilin Derivative for Topical Use in Humans
In Vitro Antibacterial Spectrum of BC-7013, a Novel Pleuromutilin Derivative for Topical Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam Against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis
Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam Against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
First Year Antimicrobial Surveillance Results for CEM-101, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia
First Year Antimicrobial Surveillance Results for CEM-101, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Activity of CEM-101, a Novel Fluoroketolide, Tested Against Invasive Isolates of N. meningitidis from a Worldwide Collection
Activity of CEM-101, a Novel Fluoroketolide, Tested Against Invasive Isolates of N. meningitidis from a Worldwide Collection, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Activity of ACHN-490, a Novel Neoglycoside Antibiotic, against Complicated Urinary Tract Infection Pathogens From the United States and Europe
Activity of ACHN-490, a Novel Neoglycoside Antibiotic, against Complicated Urinary Tract Infection Pathogens From the United States and Europe, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Antimicrobial Activity of ACHN-490, a Neoglycoside, Tested Against a Contemporary Collection of Clinical Isolates Including Problematic Antimicrobial-Resistant Phenotypes
Antimicrobial Activity of ACHN-490, a Neoglycoside, Tested Against a Contemporary Collection of Clinical Isolates Including Problematic Antimicrobial-Resistant Phenotypes, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Clinical Outcomes of Infections Caused by Extended-Spectrum ß-Lactamase (ESBL)-Producing Bacteria with Reduced Carbapenem Susceptibility
Clinical Outcomes of Infections Caused by Extended-Spectrum ß-Lactamase (ESBL)-Producing Bacteria with Reduced Carbapenem Susceptibility, Lead author: Le, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Correlation of Baseline Methicillin-Resistant Staphylococcus aureus (MRSA) Isolate Characteristics with Clinical Outcome from a Randomized Phase 4 Clinical Trial of Complicated Skin and Soft Tissue Infections
Correlation of Baseline Methicillin-Resistant Staphylococcus aureus (MRSA) Isolate Characteristics with Clinical Outcome from a Randomized Phase 4 Clinical Trial of Complicated Skin and Soft Tissue Infections, Lead author: Hogan, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Low Prevalence of fks1 Hotspot 1 Mutations in a Worldwide Collection of Candida spp.
Low Prevalence of fks1 Hotspot 1 Mutations in a Worldwide Collection of Candida spp., Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA
Assessment of Non-Antibiotic Therapeutic Agent Interactions on the Potency of Orally Administered Vancomycin
Assessment of Non-Antibiotic Therapeutic Agent Interactions on the Potency of Orally Administered Vancomycin, Lead author: Sader HS, presented at 109th annual American Society for Microbiology General Meeting (ASM), May 17 – 21, 2009, Philadelphia, PA
Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2008 (Europe, Latin America, Canada, Asia Pacific): Linezolid Global In Vitro Susceptibility Analyses
Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2008 (Europe, Latin America, Canada, Asia Pacific): Linezolid Global In Vitro Susceptibility Analyses, Lead author: Ross JE, presented at 109th annual American Society for Microbiology General Meeting (ASM), May 17 – 21, 2009, Philadelphia, PA
Linezolid Experience and Accurate Determination of Resistance (LEADER) Program 2008: USA Surveillance Report
Linezolid Experience and Accurate Determination of Resistance (LEADER) Program 2008: USA Surveillance Report, Lead author: Jones RN, presented at 109th annual American Society for Microbiology General Meeting (ASM), May 17 – 21, 2009, Philadelphia, PA
Activity of CEM-101 Tested Against Emerging Telithromycin-Resistant Beta-Haemolytic Streptococci (BHS)
Activity of CEM-101 Tested Against Emerging Telithromycin-Resistant Beta-Haemolytic Streptococci (BHS), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Novel PER-variant ß-lactamase identified in Providencia rettgeri strain from the United States (USA): Report from the SENTRY Antimicrobial Surveillance Program
Novel PER-variant ß-lactamase identified in Providencia rettgeri strain from the United States (USA): Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Castanheira M, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Pharmacodynamically-linked Variable for the Combination of Ceftaroline plus Novexel104
Pharmacodynamically-linked Variable for the Combination of Ceftaroline plus Novexel104, Lead author: Drusano GL, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Update on the Spectrum and Potency of Tigecycline Tested against 7,133 Gram-positive and -negative Pathogens from 13 Countries (2008)
Update on the Spectrum and Potency of Tigecycline Tested against 7,133 Gram-positive and -negative Pathogens from 13 Countries (2008), Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Worldwide activity of Tigecycline against Community-acquired Respiratory Tract Infection Pathogens Collected During 2006-2008
Worldwide activity of Tigecycline against Community-acquired Respiratory Tract Infection Pathogens Collected During 2006-2008, Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Report of Linezolid Resistance from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin America, Asia Pacific)
Report of Linezolid Resistance from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin America, Asia Pacific), Lead author: Ross JE, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Update on daptomycin activity and spectrum when tested against Gram-positive strains collected in European medical centres (2007-2008)
Update on daptomycin activity and spectrum when tested against Gram-positive strains collected in European medical centres (2007-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Potent Antimicrobial Activity of Daptomycin Tested against Staphylococcus aureus with Vancomycin MIC of 2 mg/L Isolated in United States and European hospitals (2006-2008)
Potent Antimicrobial Activity of Daptomycin Tested against Staphylococcus aureus with Vancomycin MIC of 2 mg/L Isolated in United States and European hospitals (2006-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Prevalence of Extended-spectrum Beta-lactamases among Enterobacteriaceae Strains from the United States (USA; 2007) and Correlation with KPC Carbapenemases
Prevalence of Extended-spectrum Beta-lactamases among Enterobacteriaceae Strains from the United States (USA; 2007) and Correlation with KPC Carbapenemases, Lead author: Castanheira M, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Prevalence and Antimicrobial Susceptibility Patterns of Methicillin-resistant S. aureus and Vancomycin-resistant E. faecium Causing Bloodstream Infections in European Hospitals (2005-2008)
Prevalence and Antimicrobial Susceptibility Patterns of Methicillin-resistant S. aureus and Vancomycin-resistant E. faecium Causing Bloodstream Infections in European Hospitals (2005-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Telavancin Activity against S. aureus and Coagulase-negative Staphylococci Collected from Clinical Infections in Europe (2007-2008)
Telavancin Activity against S. aureus and Coagulase-negative Staphylococci Collected from Clinical Infections in Europe (2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Antimicrobial Activity of Telavancin Tested against Streptococcal Species Isolates Collected from European Medical Centres (2007-2008)
Antimicrobial Activity of Telavancin Tested against Streptococcal Species Isolates Collected from European Medical Centres (2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Telavancin Antimicrobial Activity when Tested against Enterococci and Uncommonly Isolated Gram-positive Species (European Sample for 2007-2008)
Telavancin Antimicrobial Activity when Tested against Enterococci and Uncommonly Isolated Gram-positive Species (European Sample for 2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens (1998-2007)
Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens (1998-2007), Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Surveying Aminoglycoside Resistance Mechanisms: a Tool for the Development of Neoglycosides
Surveying Aminoglycoside Resistance Mechanisms: a Tool for the Development of Neoglycosides, Lead author: Armstrong, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Anti-pseudomonal Activity of Piperacillin/tazobactam: More than a Decade of Experience from the SENTRY Antimicrobial Surveillance Program (1997-2007)
Anti-pseudomonal Activity of Piperacillin/tazobactam: More than a Decade of Experience from the SENTRY Antimicrobial Surveillance Program (1997-2007), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland
Detection of cfr-carrying Staphylococcus spp. Isolates Recovered from Blood Cultures in a Spanish Hospital During a Phase III Clinical Trial of Topical Omiganan 1% Gel Versus 10% Povidone Iodine
Detection of cfr-carrying Staphylococcus spp. Isolates Recovered from Blood Cultures in a Spanish Hospital During a Phase III Clinical Trial of Topical Omiganan 1% Gel Versus 10% Povidone Iodine, Lead author: Mendes RE, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland